P J Hesketh

Summary

Affiliation: Brigham and Women's Hospital
Country: USA

Publications

  1. ncbi request reprint Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
    P J Hesketh
    Caritas St Elizabeth s Medical Center, 736 Cambridge Street, Brighton, MA, 02135 2997, USA
    Support Care Cancer 14:354-60. 2006
  2. ncbi request reprint Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:440-4. 2007
  3. doi request reprint Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide
    Paul J Hesketh
    Medical Oncology, Caritas St Elizabeth s Medical Center of Boston, HOQ Room 223, 736 Cambridge Street, Boston, MA 02135, USA
    Support Care Cancer 17:1065-70. 2009
  4. ncbi request reprint The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Brighton, MA 02135 2997, USA
    J Clin Oncol 21:4112-9. 2003
  5. ncbi request reprint Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches
    Paul J Hesketh
    Division of Hematology Oncology, Caritas St Elizabeth s Medical Center, 736 Cambridge Street, Boston, MA, USA
    Support Care Cancer 12:543-9. 2004
  6. ncbi request reprint Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:494-8. 2007
  7. ncbi request reprint New treatment options for chemotherapy-induced nausea and vomiting
    Paul J Hesketh
    Division of Hematology Oncology, Caritas St Elizabeth s Medical Center of Boston, 736 Cambridge Street, MA 02135 2907, Boston, MA, USA
    Support Care Cancer 12:550-4. 2004
  8. ncbi request reprint Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, MA 02135, USA
    J Thorac Oncol 1:991-5. 2006
  9. doi request reprint Chemotherapy-induced nausea and vomiting
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Boston, MA 02135, USA
    N Engl J Med 358:2482-94. 2008
  10. ncbi request reprint A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies
    Paul J Hesketh
    Division of Hematology and Medical Oncology, Caritas St Elizabeth s Medical Center, Boston, Massachusetts 02135, USA
    Cancer 100:859-68. 2004

Detail Information

Publications31

  1. ncbi request reprint Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
    P J Hesketh
    Caritas St Elizabeth s Medical Center, 736 Cambridge Street, Brighton, MA, 02135 2997, USA
    Support Care Cancer 14:354-60. 2006
    ..Data from two phase III trials of the NK1 antagonist aprepitant were assessed for potential effect of gender on treatment response...
  2. ncbi request reprint Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:440-4. 2007
    ..This phase II study (S9718) evaluated the antineoplastic activity and tolerability of the combination of gemcitabine and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ES-SCLC)...
  3. doi request reprint Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide
    Paul J Hesketh
    Medical Oncology, Caritas St Elizabeth s Medical Center of Boston, HOQ Room 223, 736 Cambridge Street, Boston, MA 02135, USA
    Support Care Cancer 17:1065-70. 2009
    ....
  4. ncbi request reprint The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Brighton, MA 02135 2997, USA
    J Clin Oncol 21:4112-9. 2003
    ....
  5. ncbi request reprint Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches
    Paul J Hesketh
    Division of Hematology Oncology, Caritas St Elizabeth s Medical Center, 736 Cambridge Street, Boston, MA, USA
    Support Care Cancer 12:543-9. 2004
    ..Recent evidence suggests that new scalp hypothermic regimens may be safe and effective. There remains a critical need for effective new approaches to this problem...
  6. ncbi request reprint Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:494-8. 2007
    ....
  7. ncbi request reprint New treatment options for chemotherapy-induced nausea and vomiting
    Paul J Hesketh
    Division of Hematology Oncology, Caritas St Elizabeth s Medical Center of Boston, 736 Cambridge Street, MA 02135 2907, Boston, MA, USA
    Support Care Cancer 12:550-4. 2004
    ....
  8. ncbi request reprint Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, MA 02135, USA
    J Thorac Oncol 1:991-5. 2006
    ....
  9. doi request reprint Chemotherapy-induced nausea and vomiting
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Boston, MA 02135, USA
    N Engl J Med 358:2482-94. 2008
  10. ncbi request reprint A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies
    Paul J Hesketh
    Division of Hematology and Medical Oncology, Caritas St Elizabeth s Medical Center, Boston, Massachusetts 02135, USA
    Cancer 100:859-68. 2004
    ..To investigate this issue, the authors conducted a randomized Phase II study of darbepoetin alfa administered as either a fixed dose or a weight-based dose using an accelerated correction and maintenance dosing regimen (front-loading)...
  11. ncbi request reprint Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
    P J Hesketh
    St Elizabeth s Medical Center HOQ 2, Room 225, 736 Cambridge Street, Boston, MA 02135, USA
    Eur J Cancer 39:1074-80. 2003
    ..Serotonin mediates the early vomiting process that occurs within 8-12 h following cisplatin-based chemotherapy, after which time substance P acting at NK(1) receptors becomes the dominant mediator of vomiting..
  12. ncbi request reprint Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen
    P J Hesketh
    Division of Hematology Oncology, St Elizabeth s Medical Center, Boston, MA 02135 2907, USA
    Support Care Cancer 8:46-8. 2000
    ..Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed...
  13. ncbi request reprint Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
    P J Hesketh
    Section of Medical Oncology, St Elizabeth s Medical Center, Boston, MA 02135, USA
    J Clin Oncol 17:338-43. 1999
    ..To determine the efficacy and safety of the neurokinin type 1 receptor antagonist CJ-11,974 for the control of high-dose cisplatin-induced emesis...
  14. ncbi request reprint Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting
    P J Hesketh
    Division of Hematology Oncology, St. Elizabeth's Medical Center, Boston, MA 02135-2907, USA
    Support Care Cancer 9:350-4. 2001
    ..The results of ongoing clinical trials will hopefully define the utility and appropriate place for this new class of agents in the management of chemotherapy-induced nausea and vomiting...
  15. ncbi request reprint Proposal for classifying the acute emetogenicity of cancer chemotherapy
    P J Hesketh
    St Elizabeth s Medical Center, Boston, MA 02135, USA
    J Clin Oncol 15:103-9. 1997
    ..To propose a classification of the acute emetogenicity of antineoplastic chemotherapy agents, and to develop an algorithm to define the emetogenicity of combination chemotherapy regimens...
  16. ncbi request reprint Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice
    P J Hesketh
    Division of Hematology Oncology, St Elizabeth s Medical Center, Boston, Massachusetts 02135, USA
    Oncologist 4:191-6. 1999
    ....
  17. ncbi request reprint Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
    Mark G Kris
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Support Care Cancer 13:85-96. 2005
    ..Selective antagonists of the type 3 serotonin receptor (5-HT(3)) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk...
  18. ncbi request reprint Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119
    Wallace Akerley
    University of Utah Health Science Center, Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA
    J Thorac Oncol 2:526-30. 2007
    ..To evaluate the activity of a nonplatinum-, nonetoposide-containing regimen for patients with extensive stage small cell lung cancer...
  19. ncbi request reprint Antiemetic guidelines: creating a more practical treatment approach
    Jim M Koeller
    University of Texas Health Science Center at San Antonio, Pharmacotherapy MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Support Care Cancer 10:519-22. 2002
    ..Although this document alone may not solve all the challenges with appropriate antiemetic management, it will hopefully prove to be a step in the right direction...
  20. ncbi request reprint Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
    Sant P Chawla
    Century City Hospital, Los Angeles, California 90067, USA
    Cancer 97:2290-300. 2003
    ..The current study sought to define the most appropriate dose regimen of oral aprepitant...
  21. ncbi request reprint Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
    ....
  22. ncbi request reprint Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress
    Paul J Hesketh
    Hematology Oncology, Caritas St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135, USA
    Oncology (Williston Park) 18:9-14. 2004
    ..To date, the application of pharmacogenomics to CINV has focused on variations in the metabolism of serotonin receptor antagonists by CYP 450 genotype and variations in the 5-HT3 receptor gene itself...
  23. ncbi request reprint Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027)
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, MA, USA
    J Thorac Oncol 1:537-44. 2006
    ....
  24. ncbi request reprint American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
    Mark G Kris
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 24:2932-47. 2006
    ..The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials...
  25. ncbi request reprint Acute emesis: moderately emetogenic chemotherapy
    Jørn Herrstedt
    Department of Oncology 54 B1, Copenhagen University Hospital, DK 2730 Herlev, Denmark
    Support Care Cancer 13:97-103. 2005
    ..The results of studies adding a NK(1)-receptor antagonist to this combination are awaited and might change future recommendations...
  26. ncbi request reprint Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting
    Thein H Oo
    Caritas St Elizabeth s Medical Center and Tufts University School of Medicine, Boston, MA 02135, USA
    Nat Clin Pract Oncol 2:196-201. 2005
    ..Both represent useful additions to the therapeutic armamentarium for the management of CINV...
  27. ncbi request reprint Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
    Jørn Herrstedt
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    Cancer 104:1548-55. 2005
    ..An aprepitant (APR) regimen was evaluated for prevention of nausea and emesis due to moderately emetogenic chemotherapy (MEC) over multiple cycles...
  28. ncbi request reprint The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials
    David G Warr
    Princess Margaret Hospital, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Eur J Cancer 41:1278-85. 2005
    ..In addition, even among patients who had emesis or needed rescue therapy, aprepitant was associated with a lower frequency of these events compared with the control regimen...
  29. ncbi request reprint Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    David G Warr
    Princess Margaret Hospital, Medical Oncology, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 23:2822-30. 2005
    ..This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy...
  30. ncbi request reprint Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update
    Steven M Grunberg
    University of Vermont, Burlington, Vermont 05401, USA
    Support Care Cancer 13:80-4. 2005
    ..A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed...
  31. doi request reprint Birth and re-birth
    Steven M Grunberg
    Support Care Cancer 16:979. 2008